Recruiting

EGA® vs. NMN

Sponsor:

Scott Silveira

Code:

NCT07144527

Conditions

Aging

Frailty

Exercise Tolerance

Healthy Male and Female Subjects

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Interventions

NMN, betaine, low-dose hydrogen peroxide (EGA)

Nicotinamide Mononucleotide (NMN)

Placebo

Study Details

Brief summary:

This is a randomized, double-blind, placebo-controlled, two-arm crossover clinical trial evaluating the effects of a patented age-reversal therapy, EGA®, compared to conventional nicotinamide mononucleotide (NMN) supplementation. The study will assess safety and efficacy in improving exercise tolerance and modulating biomarkers of aging in healthy older adults.

The primary outcome is cycle ergometry constant work rate (CWR) exercise tolerance, measured as time to fatigue. Secondary outcomes include changes in peak oxygen consumption (VO₂peak), critical power, anaerobic work capacity, lactate threshold, and NAD⁺ metabolite levels.

EGA® is composed of three metabolomic compounds that are endogenous to humans. The formulation has been used in prior exploratory studies and real-world applications, which have helped inform the design of this current trial.

Conditions

Aging

Frailty

Exercise Tolerance

Healthy Male and Female Subjects

Study ID

NCT07144527

Start date

Feb 21, 2026

Status verified date

Feb, 2026

Completion date

Jan 1, 2027

Anticipated

Primary completion date

Dec 30, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 60 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • Adults aged 60 to 80 years, of any sex
  • Written clearance from primary care physician confirming medical fitness to participate in an exercise-based clinical study
  • Normal or near-normal cardiovascular function to safely engage in moderate to vigorous exercise, demonstrated by either: stress echocardiogram or coronary CT angiogram within the past 12 months showing normal left ventricular function, no significant valvular heart disease, no ischemic changes, and no other clinically significant abnormalities, plus confirmation that no new cardiovascular symptoms (e.g., chest pain, dyspnea, syncope) or changes in health status have occurred since testing
  • Montreal Cognitive Assessment (MoCA) score of 26 or higher
  • Free from acute or uncontrolled chronic medical conditions that would pose a risk or interfere with study participation
  • Physically capable of engaging in structured exercise involving moderate to vigorous intensity stationary cycling
  • Successful completion of a graded exercise test (e.g., stationary bike) without significant adverse events or contraindications
  • Ability to attend at least four in-person laboratory visits in Beverly Hills, California
  • Non-smoker for at least 12 months
  • Able to provide informed consent and comply with study procedures
  • Willing to refrain from initiating new exercise, dietary supplement, or medication regimens during the study

Exclusion Criteria:

  • Severe cardiovascular disease (e.g., recent myocardial infarction <6 months, unstable angina, uncontrolled hypertension >160/100 mmHg)
  • Severe respiratory conditions (e.g., advanced COPD or other conditions preventing exercise participation)
  • Significant neurological impairments that hinder comprehension of instructions or participation in exercise
  • Terminal illness or conditions limiting life expectancy or ability to complete the study
  • Severe cognitive impairment preventing informed consent, protocol adherence, or comprehension of interventions
  • Significant orthopedic limitations or injuries that prevent safe exercise participation
  • Use of NMN, NR, or other NAD+-altering supplements within the past 14 weeks
  • Anticipated or current alcohol consumption >2 drinks per week, or unwillingness to abstain from alcohol during the study
  • Current substance abuse affecting study participation or adherence
  • Other acute or chronic health conditions judged by the investigators to pose risk or interfere with study objectives
  • Non-compliance with study requirements, withdrawal of informed consent, or unforeseen circumstances compromising completion
  • Any condition which, in the opinion of the investigator, would interfere with study participation or interpretation of results

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

experimental: Arm 1 - EGA -> Placebo

Participants receive EGA during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: EGA; Placebo.

experimental: Arm 2 - Placebo -> EGA

Participants receive Placebo during Period 1, followed by EGA during Period 2 after a washout. Assigned Interventions: Placebo; EGA.

experimental: Arm 3 - NMN -> Placebo

Participants receive Nicotinamide Mononucleotide (NMN) during Period 1, followed by Placebo during Period 2 after a washout. Assigned Interventions: NMN; Placebo.

experimental: Arm 4 - Placebo -> NMN

Participants receive Placebo during Period 1, followed by NMN during Period 2 after a washout. Assigned Interventions: Placebo; NMN.

Interventions

NMN, betaine, low-dose hydrogen peroxide (EGA)

Proprietary formulation containing NMN, betaine, and low-dose hydrogen peroxide.

Nicotinamide Mononucleotide (NMN)

Conventional NMN supplement.

Placebo

Organoleptically matched inert control.

Primary outcome measure

  • Time to Fatigue During Constant Work Rate Cycle Ergometry (tLIM). [ Time Frame: Measured at the beginning and end of each 4-week intervention period. ]

Central Contacts and Locations

Locations

Medical Office of Dr. Robert Huizenga MD

Recruiting

Beverly Hills, California, United States, 90210

Contacts

Nancy Castellanos, BA

310-666-6585huizenganurse@robertsondx.com

Ashley Erazo, Medical Assistant

310-657-9191huizenganurse@robertsondx.com

Principal Investigator:

Scott R Silveira, Ph.D. (c)

More Information

Sponsor

Scott Silveira

Last update posted

Feb 20, 2026

Last verified

Feb, 2026

Keywords

  • Nicotinamide Mononucleotide
  • NAD+ Metabolism
  • Exercise Tolerance
  • Aging
  • Older Adults
  • Betaine
  • Hydrogen Peroxide (low-dose, dietary)
  • High Intensity Interval Training
  • VO2peak
  • Lactate Threshold
  • Critical Power
  • Anaerobic Work Capacity
  • Healthy Volunteers

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Scott Silveira on 2026-02-20.